govt.fyi
Back to HB 1916
Arkansas General Assembly· HB 1916Notification that HB1916 is now Act 979

An act TO AMEND THE PROTECTING MINORS FROM MEDICAL 10 MALPRACTICE ACT OF 2023, the official text

Shown verbatim: the complete text as captured from the official PDF posted by the Arkansas General Assembly, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
Stricken language would be deleted from and underlined language would be added to present law.

1 State of Arkansas           As Engrossed: H4/2/25
2 95th General Assembly
                                   A Bill

3 Regular Session, 2025                                           HOUSE BILL 1916

4

5 By: Representative Bentley

6 By: Senator A. Clark

7

8                             For An Act To Be Entitled

9   AN ACT TO AMEND THE PROTECTING MINORS FROM MEDICAL

10  MALPRACTICE ACT OF 2023; TO INCLUDE GENDER-AFFIRMING

11  INTERVENTIONS AS A RIGHT OF ACTION FOR MEDICAL

12  MALPRACTICE; AND FOR OTHER PURPOSES.

13

14

15                                     Subtitle

16                       TO AMEND THE PROTECTING MINORS FROM

17                       MEDICAL MALPRACTICE ACT OF 2023; AND TO

18                       INCLUDE GENDER-AFFIRMING INTERVENTIONS

19                       AS A RIGHT OF ACTION FOR MEDICAL

20                       MALPRACTICE.

21

22 BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF ARKANSAS:

23

24  SECTION 1. Arkansas Code � 16-114-401, concerning definitions within

25 the Protecting Minors from Medical Malpractice Act of 2023, is amended to add

26 an additional subdivision to read as follows:

27  (6) "Gender-affirming intervention" means an intervention to

28 support a patient's identification with the gender opposite of his or her

29 biological sex, including without limitation:

30                       (A) Puberty blockers; and

31                       (B) Cross-sex hormone therapy.

32

33  SECTION 2. Arkansas Code � 16-114-402 and � 16-114-403 are amended to

34 read as follows:

35  16-114-402. Right of action.

36  (a) A healthcare professional who performs a gender transition

    *JMB609*                                                      04-02-2025 09:49:07 JMB609
    As Engrossed: H4/2/25                                                  HB1916

1 procedure or a mental health professional who performs gender-affirming

2 intervention on a minor is liable to the minor if the minor is injured,

3 including without limitation any physical, psychological, emotional, or

4 physiological injury, by the gender transition procedure, gender-affirming

5 intervention, related treatment, or the after effects of the gender

6 transition procedure, or gender-affirming intervention, or related treatment.

7   (b)(1) A minor injured as provided under subsection (a) of this

8 section, or a representative of a minor injured as provided under subsection

9 (a) of this section who receives a gender transition procedure or a gender-

10 affirming intervention, including without limitation a parent or legal

11 guardian of a minor injured as provided under subsection (a) of this section

12 who receives a gender transition procedure or a gender-affirming intervention

13 acting on behalf of the minor, may bring a civil action against the

14 healthcare professional who performed the gender transition procedure or

15 gender-affirming intervention on the minor in a court of competent

16 jurisdiction for:

17                    (A) Declaratory or injunctive relief;

18                    (B) Compensatory damages;

19                    (C) Punitive damages; and

20                    (D) Attorney's fees and costs.

21  (2) A civil action under subdivision (b)(1) of this section

22 shall be filed not later than fifteen (15) years after the date on which the

23 minor turns eighteen (18) years of age, or would have turned eighteen (18)

24 years of age if the minor died before turning eighteen (18) years of age.

25

26  16-114-403. Safe harbor.

27  (a) It is a defense to a civil action brought under � 16-114-402 that,

28 before performing a gender transition procedure or a gender-affirming

29 intervention on a minor:

30  (1) The healthcare professional documented the minor's perceived

31 gender or perceived sex for two (2) continuous years, and the minor's

32 perceived gender or perceived sex was invariably inconsistent with the

33 minor's biological sex throughout the two (2) years;

34  (2) To the extent that the minor suffered from a mental health

35 concern, at least two (2) healthcare professionals, including at least one

36 (1) mental health professional, certified in writing that the gender

                              2                       04-02-2025 09:49:07 JMB609
    As Engrossed: H4/2/25                                                   HB1916

1 transition procedure was the only way to treat the mental health concern;

2             (3) At least two (2) healthcare professionals, including at

3 least one (1) mental health professional, certified in writing that the minor

4 suffered from no other mental health concerns, including without limitation

5 depression, eating disorders, autism, attention deficit hyperactivity

6 disorder, intellectual disability, or psychotic disorders; and

7             (4) The healthcare professional received the voluntary and

8 informed consent of the parent or legal guardian of the minor and the minor

9 as provided in subsection (b) of this section.

10  (b) Consent to a gender transition procedure or a gender-affirming

11 intervention is voluntary and informed only if, at least thirty (30) days

12 before the first treatment of the gender transition procedure or gender-

13 affirming intervention and during every subsequent medical visit for

14 treatment during the following six (6) months, the minor and the minor's

15 parent or legal guardian receive verbal notice and written notice in at least

16 14-point, proportionally spaced typeface that state the following facts,

17 verbatim:

18            "If your child begins one (1) of these treatments, it may

19 actually worsen the discordance and thus increase the likelihood that your

20 child will need additional and more serious interventions to address the

21 worsening condition. For example, if your child begins socially transitioning

22 or taking puberty blockers, that treatment may significantly increase the

23 likelihood that your child's discordance will worsen and lead to your child

24 eventually seeking cross-sex hormones or even surgery to remove some of your

25 child's body parts.

26            Sweden, Finland, and the United Kingdom have conducted systematic

27 reviews of evidence and concluded that there is no evidence that the

28 potential benefits of puberty blockers and cross-sex hormones for this

29 purpose outweigh the known or assumed risks.

30            Medical authorities in Sweden, Finland, and the United Kingdom

31 have since recommended psychotherapy as the first line of treatment for youth

32 gender dysphoria, with drugs and surgeries reserved as a measure of last

33 resort. Medical authorities in France have advised `great caution' when

34 prescribing hormones for gender dysphoria.

35            There are people who underwent gender transition treatments or

36 gender-affirming interventions as minors and later regretted that decision

                           3                      04-02-2025 09:49:07 JMB609
    As Engrossed: H4/2/25                                                   HB1916

1 and the physical harm that these treatments caused, and the total percentage

2 of people who experience this regret is unknown. Some estimate that the rate

3 is below two percent (2%), but that estimate is based on studies done on

4 adults who transitioned as adults or on minors who transitioned under highly

5 restrictive and controlled conditions.

6   Sometimes gender transition treatments or gender-affirming

7 interventions have been proposed as a way to reduce the chances of a minor

8 committing suicide due to discordance between the minor's sex and his or her

9 perception, but the rates of actual suicide from this discordance remain

10 extremely low. Furthermore, as recognized by health authorities in Europe,

11 there is no evidence that suicidality is caused by `unaffirmed' gender or

12 that gender transition treatments are causally linked to a reduction in

13 serious suicidal attempts or ideations.

14  For puberty blockers:

15  Puberty blockers are not approved for this purpose by the United

16 States Food and Drug Administration, which is the federal agency that

17 determines which drugs are safe and effective for humans to use. Claims about

18 puberty blockers' safety and efficacy are based on their use for precocious

19 puberty, a different condition in which normal puberty is allowed to resume

20 once the patient reaches the appropriate age. Studies on the benefits of

21 using puberty blockers for gender dysphoria are notoriously weak. Puberty

22 blockers are not fully reversible because, among other risks, puberty

23 blockers may intensify a minor's discordance and cause it to persist. Puberty

24 blockers increase the risk of your child being sterilized, meaning that he or

25 she will never be able to have children. Puberty blockers may also cause

26 diminished bone density for your child, increasing the risk of fracture and

27 early osteoporosis. Puberty blockers may also prevent your child from ever

28 being able to engage in sexual activity or achieve orgasm for the rest of

29 your child's life. There is no research on the long-term risks to minors of

30 persistent exposure to puberty blockers. The full effects of puberty blockers

31 on brain development and cognition are unknown.

32  For cross-sex hormones:

33  The use of cross-sex hormones in males is associated with

34 numerous health risks, such as thromboembolic disease, including without

35 limitation blood clots; cholelithiasis, including gallstones; coronary artery

36 disease, including without limitation heart attacks; macroprolactinoma, which

                             4                      04-02-2025 09:49:07 JMB609
    As Engrossed: H4/2/25                                                   HB1916

1 is a tumor of the pituitary gland; cerebrovascular disease, including without

2 limitation strokes; hypertriglyceridemia, which is an elevated level of

3 triglycerides in the blood; breast cancer; and irreversible infertility. The

4 use of cross-sex hormones in females is associated with risks of

5 erythrocytosis, which is an increase in red blood cells; severe liver

6 dysfunction; coronary artery disease, including without limitation heart

7 attacks; hypertension; and increased risk of breast and uterine cancers. Once

8 a minor begins cross-sex hormones, the minor may need to continue taking

9 those hormones for many years and possibly for the remainder of the minor's

10 life. The cost of these hormones may be tens of thousands of dollars. If the

11 use of cross-sex hormones leads to surgery, the total cost of transitioning

12 may exceed one hundred thousand dollars ($100,000).

13  For surgical procedures:

14  The dangers, risks, complications, and long-term concerns

15 associated with these types of procedures are almost entirely unknown. There

16 are no long-term studies on either the effectiveness or safety of these

17 surgical procedures.".

18

19                         /s/Bentley

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

                           5                            04-02-2025 09:49:07 JMB609
Every fact on this page links to its source, starting with the official bill record.